Cel-Sci (CVM) vs Impact BioMedical (IBO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Impact BioMedical (IBO) has outperformed Cel-Sci (CVM) over the past year, losing 47.4% versus a loss of 80.6%. Impact BioMedical is the larger company by market cap ($35.1 million vs $34.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CVM | IBO |
|---|---|---|
| Share price | $1.95 | $4.11 |
| Market cap | $34.30M | $35.11M |
| 1-day change | -8.45% | -8.26% |
| YTD return | -62.93% | -35.70% |
| 1-year return | -80.56% | -47.38% |
| 5-year return | -99.38% | — |
| P/E ratio (TTM) | — | 0.37 |
| EPS (TTM) | $-1.69 | $11.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.39 | $10.51 |
| 52-week low | $0.89 | $4.10 |
| Distance from 52-week high | -81.23% | -60.88% |
| Analyst consensus | none | — |
| Avg. price target upside | +541.03% | — |
| Average volume | 241.50K | 11.61K |
| Shares outstanding | 17.59M | 8.54M |
| Employees | — | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBO has outperformed CVM by 33.2 percentage points over the past year.
About Cel-Sci
CVM stock →CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Healthcare · Biotechnology
About Impact BioMedical
IBO stock →Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.
Healthcare · Biotechnology · 2 employees
CVM vs IBO FAQ
Which is bigger, Cel-Sci or Impact BioMedical?
Impact BioMedical (IBO) is larger, with a market capitalization of $35.11M compared with $34.30M for Cel-Sci (CVM).
Which stock has performed better over the past year, CVM or IBO?
IBO returned -47.38% over the past 12 months, compared with -80.56% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are Cel-Sci and Impact BioMedical in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.